Physician profile
Amanda Bryan
NPI 1902338262
$585.17
in general payments reported to CMS, 2019-2025
12 companies · $15.72 in 2025
The $15.72 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.80 · 2021: $231 · 2022: $231 · 2023: $50.12 · 2024: $38.10 · 2025: $15.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $103.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $122.89 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $115.99 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $104.79 | 2021-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $58.30 | 2021 | |
| Abbvie INC. | $39.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.24 | 2021-2025 | Lifevest |
| Alexion Pharmaceuticals, INC. | $21.27 | 2022 | |
| Tris Pharma INC | $19.17 | 2024 | Dyanavel Xr |
| Medtronic, INC. | $18.95 | 2022 | |
| Glaxosmithkline, LLC. | $18.93 | 2024 | Shingrix, Arexvy |
| Allergan, INC. | $18.80 | 2020 | |
| Merck Sharp & Dohme LLC | $15.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.